Sandrine H.
- Country
- France
- Department
- Medical Oncology Department
Research Overview
- Assessment of 64Cu-ATSM PET/CT as a Predictor of Neoadjuvant Therapy Response in Locally Advanced Rectal Adenocarcinoma
- Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
- Evaluation of STX-721 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Specific Mutations
Data & Insights
Has run more than one trial at 410 of 716 partner sites.
Specializations
Lung Cancer Expertise
Specializes in treating various forms of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular focus on advanced and metastatic cases.
- Limited-stage SCLC treatment
- ROS1-positive NSCLC therapy
- EGFR-mutated NSCLC management
- Metastatic squamous NSCLC
Actively involved in evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.
Gastrointestinal Oncology
Focuses on innovative treatments for various gastrointestinal cancers, including pancreatic adenocarcinoma, gastric cancer, and colon cancer.
- Advanced pancreatic cancer therapy
- Gastroesophageal junction cancer treatment
- High-risk stage III colon cancer management
- Resectable gastric cancer approaches
Specializes in both early-stage and advanced gastrointestinal malignancies.
Therapeutic Approaches
Employs diverse treatment modalities including immunotherapy, targeted therapy, and combination treatments.
- Novel antibody therapeutics
- Chemoradiation protocols
- First-line treatment strategies
- Perioperative therapy
Focuses on personalized treatment approaches for various cancer types.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.